Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2021, at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the company's website. Additionally, AtriCure will attend one-on-one investor meetings at the Needham Annual Growth Conference on January 14, 2021. The company is known for its innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices, which are widely used in Afib treatment.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1 to 3, 2020. The company focuses on innovative technologies for Afib treatment, impacting over 33 million individuals globally. Their Isolator® Synergy™ Ablation System is the first FDA-approved device for persistent Afib treatment, while the AtriClip® Left Atrial Appendage Exclusion System is the most widely sold LAA management device. For more details, visit AtriCure's Investor Relations page.
AtriCure, Inc. (Nasdaq: ATRC) announced its third quarter 2020 results, reporting revenue of $54.8 million, a decrease of 3.3% year-over-year, largely due to the COVID-19 pandemic affecting surgical procedures. U.S. revenue fell by 3.1% to $44.7 million, while international revenue dropped 4.1% to $10.1 million. Gross profit was $40.3 million with a gross margin of 73.7%. The net loss per share improved to $0.11 from $0.25 in Q3 2019. For Q4 2020, the company expects revenue between $56 million and $60 million, with a full-year guidance of $205 million to $209 million.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in two investor conferences. The management team will present at the Stifel Healthcare Conference on November 18, 2020, at 11:20 a.m. ET, with a live webcast available on their website. Additionally, they will engage in one-on-one meetings at the Canaccord MedTech and Diagnostics Forum on November 19, 2020, without a webcast. AtriCure’s innovations are crucial in managing Afib, impacting over 33 million people globally and showcasing their FDA-approved Isolator® Synergy™ Ablation System.
AtriCure, a leader in treatments for atrial fibrillation (Afib), announced that it will release its third quarter 2020 financial results on November 5, 2020. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day. AtriCure's innovative technologies, like the FDA-approved Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System, are widely utilized by medical professionals for Afib management, affecting over 33 million people globally. For further details, visit AtriCure.com.